The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,007
Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia
Patel, J. L., Schumacher, J. A., Frizzell, K., Sorrells, S., Shen, W., Clayton, A. L., Jattani, R. P., & Kelley, T. W. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.027 · Cited by 60
Chang, C.-J., Kotini, A. G., Olszewska, M., Georgomanoli, M., Teruya‐Feldstein, J., Sperber, H., Sánchez, R., DeVita, R. J., Martins, T. J., Abdel-Wahab, O. I., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.020 · Cited by 59
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
Sung, P. J., Sugita, M., Koblish, H. K., Perl, A. E., & Carroll, M. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029850 · Cited by 59
Dalton, W. B., Helmenstine, E., Pieterse, L., Li, B., Gocke, C. D., Donaldson, J. M., Xiao, Z., Gondek, L. P., Ghiaur, G., Gojo, I., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001127 · Cited by 65
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia
Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021) · Nature Communications · doi:10.1038/s41467-021-27472-5 · Cited by 62
Cao, Y., Chen, G., Wu, G., Zhang, X., McDermott, J., Chen, X., Chi, X., Jiang, Q., Chen, Z., Zeng, Y., et al. (2018) · Genome Research · doi:10.1101/gr.235747.118 · Cited by 59
The multifaceted roles of cohesin in cancer
Nardo, M. D., Pallotta, M. M., & Musio, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02321-5 · Cited by 62
Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
Wang, E. S., Montesinos, P., Foran, J. M., Erba, H. P., Arboli, E. R., Fedorov, K., Heiblig, M., Heidel, F. H., Altman, J. K., Baer, M. R., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01694 · Cited by 58
Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017) · Blood · doi:10.1182/blood-2017-03-734533 · Cited by 58
Heuser, M., Gabdoulline, R. R., Löffeld, P., Dobbernack, V., Kreimeyer, H., Pankratz, M., Flintrop, M., Liebich, A., Klesse, S., Panagiota, V., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3027-5 · Cited by 58
Self-citationSasca, D., Yun, H., Giotopoulos, G., Szybinski, J., Evan, T., Wilson, N. K., Gerstung, M., Gallipoli, P., Green, A. R., Hills, R. K., et al. (2019) · Blood · doi:10.1182/blood.2019001553 · Cited by 60
Self-citationOvercoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Lam, S. S. Y., & Leung, A. Y. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041537 · Cited by 58
Øbro, N. F., Grinfeld, J., Belmonte, M., Irvine, M., Shepherd, M. S., Rao, T. N., Karow, A., Riedel, L. M., Harris, O. B., Baxter, E. J., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000371 · Cited by 58
Self-citationAzacitidine in adult patients with acute myeloid leukemia
Schuh, A. C., Döhner, H., Pleyer, L., Seymour, J. F., Fenaux, P., & Dombret, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.010 · Cited by 57
Self-citationBoucai, L., Falcone, J., Ukena, J., Coombs, C. C., Zehir, A., Ptashkin, R. N., Berger, M. F., Levine, R. L., & Fagin, J. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00803 · Cited by 57
Ferrara, F., Lessi, F., Vitagliano, O., Birkenghi, E., & Rossi, G. (2019) · Cancers · doi:10.3390/cancers11020224 · Cited by 57
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
Stuani, L., Sabatier, M., & Sarry, J. (2019) · BMC Biology · doi:10.1186/s12915-019-0670-4 · Cited by 66
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor
Taylor, J., Donoghue, M. T. A., Ho, C., Petrova‐Drus, K., Al‐Ahmadie, H. A., Funt, S. A., Zhang, Y., Aypar, U., Rao, P., Chavan, S. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139682 · Cited by 57
Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
Lee, W.-H. S., Ye, Z., Cheung, A. M. S., Goh, Y., Oh, H. L. J., Rajarethinam, R., Yeo, S. P., Soh, M. K., Chan, E. H. L., Tan, L. K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0155 · Cited by 57
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers
He, L., Zhong, Z., Chen, M., Liang, Q., Wang, Y., & Tan, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775084 · Cited by 57
Ho, J. N. H. G., Schmidt, D., Lowinus, T., Ryoo, J., Dopfer, E.-P., Núñez, N. G., Costa-Pereira, S., Toffalori, C., Punta, M., Fetsch, V., et al. (2022) · Blood · doi:10.1182/blood.2022016082 · Cited by 57
Schönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., Fabisch, C., Brümmendorf, T. H., Burchert, A., le Coutre, P., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01648-4 · Cited by 57
Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
Kim, J. C., Chan‐Seng‐Yue, M., Ge, S., Zeng, A. G. X., Ng, K., Gan, O. I., García‐Prat, L., Figueroa, E. F., Woo, T., Zhang, A. X. W., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01429-4 · Cited by 61
Ball, M., List, A. F., & Padron, E. (2016) · Blood · doi:10.1182/blood-2016-07-692988 · Cited by 63
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Maiti, A., Naqvi, K., Kadia, T. M., Borthakur, G. M., Takahashi, K., Bose, P., Daver, N. G., Patel, A. P., Alvarado, Y., Ohanian, M. N., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.009 · Cited by 57
Bazarbachi, A. A., Labopin, M., Battipaglia, G., Djabali, A., Forcade, É., Arcese, W., Socié, G., Blaise, D., Halter, J. P., Gerull, S., et al. (2019) · Clinical Hematology International · doi:10.2991/chi.d.190310.001 · Cited by 57
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00189 · Cited by 57
Self-citationFunctional Classification of TP53 Mutations in Acute Myeloid Leukemia
Dutta, S., Pregartner, G., Rücker, F. G., Heitzer, E., Zebisch, A., Bullinger, L., Berghold, A., Döhner, K., & Sill, H. (2020) · Cancers · doi:10.3390/cancers12030637 · Cited by 60
Self-citationYasuda, T., Sanada, M., Kawazu, M., Kojima, S., Tsuzuki, S., Ueno, H., Iwamoto, E., Iijima‐Yamashita, Y., Yamada, T., Kanamori, T., et al. (2021) · Blood · doi:10.1182/blood.2021011921 · Cited by 60
Optical mapping reveals a higher level of genomic architecture of chained fusions in cancerPreprint
Chan, E. K. F., Cameron, D., Petersen, D. C., Lyons, R. J., Baldi, B. F., Papenfuss, A. T., Thomas, D. M., & Hayes, V. M. (2018) · Genome Research · doi:10.1101/gr.227975.117 · Cited by 57
Nucleophosmin in Its Interaction with Ligands
Cela, I., Matteo, A. D., & Federici, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144885 · Cited by 56
IDH Inhibitors in AML—Promise and Pitfalls
McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 56
Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
Kantarjian, H. M., Short, N. J., Fathi, A. T., Marcucci, G., Ravandi, F., Tallman, M. S., Wang, E. S., & Wei, A. H. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.05.016 · Cited by 56
West, R. R., Calvo, K. R., Embree, L. J., Wang, W., Tuschong, L. M., Bauer, T. R., Tillo, D., Lack, J., Droll, S. H., Hsu, A. P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005065 · Cited by 56
Peng, M., Ren, J., Jing, Y., Jiang, X., Xiao, Q., Huang, J., Tao, Y., Li, L., Wang, X., Yang, Z., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12168 · Cited by 56
Novel precision medicine approaches and treatment strategies in hematological malignancies
Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P. H., Soulier, J., Hutchings, M., Östling, P., Cavelier, L. B., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13697 · Cited by 56
In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis
Lara‐Astiaso, D., Goñi‐Salaverri, A., Mendieta-Esteban, J., Narayan, N., del Valle, C., Groß, T., Giotopoulos, G., Beinortas, T., Navarro-Alonso, M., Aguado‐Alvaro, L. P., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01471-2 · Cited by 57
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 63
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 59
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia
Lazarian, G., Guièze, R., & Wu, C. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0822 · Cited by 58
Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia
Salerno, L., Romeo, G., Modica, M. N., Amata, E., Sorrenti, V., Barbagallo, I. A., & Pittalà, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.031 · Cited by 56
Romero‐Pérez, L., Surdez, D., Brunet, E., Delattre, O., & Grünewald, T. G. P. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.001 · Cited by 56
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1
Carmichael, C., Wang, J., Nguyen, T. M., Kolawole, O., Benyoucef, A., Mazière, C. D., Milne, A. R., Samuel, S., Gillinder, K. R., Hediyeh-zadeh, S., et al. (2020) · Blood · doi:10.1182/blood.2019002548 · Cited by 56
Wang, R., Chen, C., Jing, Y., Qin, J., Li, Y., Chen, G., Zhou, W., Li, Y., Wang, J., Li, D., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3467 · Cited by 56
Fagnan, A., Bagger, F. O., Piqué‐Borràs, M., Ignacimouttou, C., Caulier, A., Lopez, C. K., Robert, E., Uzan, B., Gelsi‐Boyer, V., Aid, Z., et al. (2020) · Blood · doi:10.1182/blood.2019003062 · Cited by 55
Nuclear NAD + homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells
Shi, X. E., Jiang, Y., Kitano, A., Hu, T., Murdaugh, R. L., Li, Y., Hoegenauer, K. A., Chen, R., Takahashi, K., & Nakada, D. (2021) · Science Advances · doi:10.1126/sciadv.abf3895 · Cited by 55
Significance of NPM1 Gene Mutations in AML
Hindley, A., Catherwood, M. A., McMullin, M. F., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810040 · Cited by 57
Wang, X., Zhu, W., Wang, Z., Huang, J.-B., Wang, S., Bai, F., Li, T., Zhu, Y., Zhao, J., Yang, X., et al. (2021) · Theranostics · doi:10.7150/thno.63417 · Cited by 56
Full circle: a brief history of cohesin and the regulation of gene expression
Horsfield, J. A. (2022) · FEBS Journal · doi:10.1111/febs.16362 · Cited by 57
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML
Wang, E. S., Goldberg, A. D., Tallman, M. S., Walter, R. B., Karanes, C., Sandhu, K., Vigil, C. E., Collins, R. H., Jain, V. K., & Stone, R. M. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01061 · Cited by 55
Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia
Lal, R., LIND, K., Heitzer, E., Ulz, P., Aubell, K., Kashofer, K., Middeke, J. M., Thiede, C., Schulz, E., Rosenberger, A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751008 · Cited by 56
Self-citationImpact of somatic and germline mutations on the outcome of systemic mastocytosis
Muñoz‐González, J. I., Jara‐Acevedo, M., Álvarez‐Twöse, I., Merker, J. D., Teodósio, C., Hou, Y., Henriques, A., Roskin, K. M., Sánchez‐Muñoz, L., Tsai, A. G., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020628 · Cited by 55
Wagner, S., Vadakekolathu, J. N., Tasian, S. K., Altmann, H., Bornhäuser, M., Pockley, A. G., Ball, G., & Rutella, S. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030726 · Cited by 55
STAT3 transcription factor as target for anti-cancer therapy
Mohassab, A. M., Hassan, H. A., Abdelhamid, D. S., & Abdel‐Aziz, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00156-5 · Cited by 57
An, N., Khan, S., Imgruet, M. K., Gurbuxani, S. K., Konecki, S. N., Burgess, M. R., & McNerney, M. E. (2018) · Blood · doi:10.1182/blood-2017-10-810028 · Cited by 55
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V. S., Maecker, H. T., Rowley, J. W., Gotlib, J. R., Zehnder, J. L., & Krishnan, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100425 · Cited by 55
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Fleischmann, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2021) · Cancers · doi:10.3390/cancers13225722 · Cited by 59
Loke, J. C. T., Labopin, M., Craddock, C., Cornelissen, J. J., Labussière‐Wallet, H., Wagner-Drouet, E., van Gorkom, G. N. Y., Schaap, N. P., Kröger, N. M., Veelken, J. H., et al. (2022) · Cancer · doi:10.1002/cncr.34268 · Cited by 54
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Othman, J., Potter, N. E., Mokretar, K., Taussig, D. C., Khan, A. B., Krishnamurthy, P., Latif, A., Cahalin, P., Aries, J. A., Amer, M., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01994-x · Cited by 54
Self-citationMitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis
Gozdecka, M., Dudek, M., Wen, S., Gu, M., Stopforth, R. J., Rak, J. M., Damaskou, A., Grice, G. L., McLoughlin, M. A., Bond, L., et al. (2025) · Nature · doi:10.1038/s41586-025-08980-6 · Cited by 56
RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
Loke, J. C. T., Assi, S. A., Imperato, M. R., Ptasinska, A., Cauchy, P., Grabovska, Y., Martinez-Soria, N., Raghavan, M., Delwel, R., Cockerill, P. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.005 · Cited by 56
Tawana, K., Drazer, M. W., & Churpek, J. E. (2018) · Leukemia · doi:10.1038/s41375-018-0051-y · Cited by 55
Natural scaffolds in anticancer therapy and precision medicine
Mazumder, A., Cerella, C., & Diederich, M. F. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.009 · Cited by 54
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
Eisfeld, A., Kohlschmidt, J., Mrózek, K., Mims, A. S., Walker, C. J., Blachly, J. S., Nicolet, D., Orwick, S. J., Maharry, S. E., Carroll, A. J., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0147-4 · Cited by 54
Trisomy 8 in acute myeloid leukemia
Hemsing, A. L., Hovland, R., Tsykunova, G., & Reikvam, H. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1657400 · Cited by 56
Kattih, B., Shirvani, A., Klement, P., Garrido, A. M., Gabdoulline, R. R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., Thol, F. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01043-x · Cited by 57
Self-citationFrom Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells
Grignano, É., Birsen, R., Chapuis, N., & Bouscary, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586530 · Cited by 57
Shi, H., Li, X., Chen, Y., Zhang, X., Wu, Y., Wang, Z., Chen, P.-H., Dai, H.-Q., Ji, F., Chatterjee, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.534171 · Cited by 54
Giacopelli, B., Wang, M., Sher, A. C., Wu, Y.-Z., Schultz, A. R., Schmutz, M., Blachly, J. S., Eisfeld, A., Mundy-Bosse, B. L., Vosberg, S., et al. (2021) · Genome Research · doi:10.1101/gr.269233.120 · Cited by 58
Self-citationStengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53
Wheeler, E. C., Vora, S., Mayer, D., Kotini, A. G., Olszewska, M., Park, S. S., Guccione, E., Teruya‐Feldstein, J., Silverman, L. R., Sunahara, R. K., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0508 · Cited by 54
Middeke, J. M., Metzeler, K. H., Röllig, C., Krämer, M., Eckardt, J., Stasik, S., Greif, P. A., Spiekermann, K., Rothenberg‐Thurley, M., Krug, U. O., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004934 · Cited by 53
Eckardt, J., Röllig, C., Metzeler, K. H., Krämer, M., Stasik, S., Georgi, J.-A., Heisig, P., Spiekermann, K., Krug, U. O., Braess, J., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280027 · Cited by 53
Penter, L., Liu, Y., Wolff, J. O., Yang, L., Taing, L., Jhaveri, A., Southard, J., Patel, M., Cullen, N. M., Pfaff, K. L., et al. (2023) · Blood · doi:10.1182/blood.2022018246 · Cited by 55
Lin, P., Li, H., Fan, S., Yuan, T., Chen, M., Hsu, Y., Yang, Y., Li, L., Yeh, S., Bai, L., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.969 · Cited by 53
Casado, P., Wilkes, E. H., Miraki‐Moud, F., Hadi, M. M., Rio‐Machín, A., Rajeeve, V., Pike, R., Iqbal, S., Marfà, S., Lea, N. C., et al. (2017) · Leukemia · doi:10.1038/s41375-018-0032-1 · Cited by 53
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Marquis, M., Beaubois, C., Lavallée, V., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., Wei, A. H., Ting, S. B., Fleming, S. A., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0103-6 · Cited by 54
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
Terao, T., & Minami, Y. (2019) · Cells · doi:10.3390/cells8040312 · Cited by 53
SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness
Nguyen, C. H., Glüxam, T., Schlerka, A., Bauer, K., Grandits, A. M., Hackl, H., Dovey, O. M., Zöchbauer‐Müller, S., Cooper, J. L., Vassiliou, G. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45579-0 · Cited by 53
Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia
Ghannam, J. Y., Dillon, L. W., & Hourigan, C. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.16362 · Cited by 53
Grimm, J., Jentzsch, M., Bill, M., Goldmann, K., Schulz, J. C., Niederwieser, D. W., Platzbecker, U., & Schwind, S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001904 · Cited by 53
Maifrede, S., Le, B. V., Nieborowska-Skorska, M., Golovine, K. V., Sullivan-Reed, K., Dunuwille, W. M. B., Nacson, J., Hulse, M., Keith, K., Madžo, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3761 · Cited by 57
Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
Park, H., Shin, H. C., Yang, H., Heo, J., Ki, C., Kim, H. S., Kim, J., Hahn, S. Y., Chung, Y. J., Kim, S. W., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00907-6 · Cited by 52
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Turkalj, S., Radtke, F. A., & Vyas, P. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000914 · Cited by 54
Pratz, K. W., Cherry, M. A., Altman, J. K., Cooper, B., Podoltsev, N. A., Cruz, J. C., Lin, T. L., Schiller, G. J., Jurcic, J. G., Asch, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02721 · Cited by 52
Russell, N. H., Wilhelm-Benartzi, C. S., Othman, J., Dillon, R. J., Knapper, S., Batten, L. M., Canham, J. E., Hinson, E. L., Betteridge, S., Overgaard, U. M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00943 · Cited by 52
Self-citationMultifaceted role of the polycomb-group gene EZH2 in hematological malignancies
Sashida, G., & Iwama, A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2124-x · Cited by 55
Meggendorfer, M., Haferlach, C., Kern, W., & Haferlach, T. (2017) · Haematologica · doi:10.3324/haematol.2017.166173 · Cited by 54
Slade, M., DiPersio, J. F., Westervelt, P., Vij, R., Schroeder, M. A., & Romee, R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.019 · Cited by 52
Das, A. B., Kakadia, P. M., Wojcik, D. P., Pemberton, L. C., Browett, P., Bohlander, S. K., & Vissers, M. C. M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0242-4 · Cited by 54
KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements
Au, Y. Z., Gu, M., Braekeleer, E. D., Gozdecka, M., Aspris, D., Tarumoto, Y., Cooper, J. L., Yu, J., Ong, S. H., Chen, X. X., et al. (2020) · Leukemia · doi:10.1038/s41375-020-1001-z · Cited by 52
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 52
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinicPreprint
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 53
Cohesin mutations in myeloid malignancies
Jann, J.-C., & Tóthová, Z. (2021) · Blood · doi:10.1182/blood.2019004259 · Cited by 52
van der Werf, I. M., Wojtuszkiewicz, A., Meggendorfer, M., Hütter, S., Baer, C. R., Heymans, M. W., Valk, P. J. M., Kern, W., Haferlach, C., Janssen, J. J. W. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004556 · Cited by 52
Zhao, P., Ni, M., Ma, D., Fang, Q., Zhang, Y., Li, Y., Huang, Y., Chen, Y., Chai, X., Zhan, Y., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04674-x · Cited by 51
Leukemia segmentation and classification: A comprehensive survey
Saleem, S., Amin, J., Sharif, M., Mallah, G. A., Kadry, S., & Gandomi, A. H. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106028 · Cited by 51
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Chaer, F. E., Hourigan, C. S., & Zeidan, A. M. (2023) · Blood · doi:10.1182/blood.2022017808 · Cited by 51
Implications of molecular genetic diversity in myelodysplastic syndromes
Bejar, R. L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000313 · Cited by 53
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
